ADMA Biologics Inc vs Cisco Systems Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Cisco Systems Inc trades at $121.24 (market cap $483.10B). The key difference: Cisco Systems Inc is far larger — about 221.6× ADMA Biologics Inc's market cap, and Cisco Systems Inc pays a 1.37% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CSCO | |
|---|---|---|
Market Cap | $2.18B | $483.10B |
Sector | Health | Technology |
52-Week High | $20.38 | $130.00 |
52-Week Low | $7.60 | $66.20 |
Enterprise Value | $2.25B | $497.76B |
Volume | — | 22,887,319 |
Dividend Yield | — | 1.37% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Cisco Systems (CSCO) trades at $120.43, down 0.82% on the day, amid a bullish technical outlook and strong earnings beats. The stock shows robust fundamentals with a 64.33% gross margin and consistent quarterly EPS outperformance. Recent AI cybersecurity initiatives and partner expansions fuel positive sentiment, with a consensus price target of $133.25 implying upside potential.
The outlook remains favorable given AI-driven growth catalysts and solid cash flow, though elevated valuation ratios and competitive pressures pose risks. Analyst consensus leans bullish with 52% buy ratings, supporting a constructive view for investors seeking exposure to networking and cybersecurity trends.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →